Date Document
23/12/2016 Customer Newsletter December 2016
15/12/2016 FerriScan use showcased at ASH conference
01/12/2016 Equity Research Report Released
28/11/2016 Initial Director's Interest Notice
24/11/2016 Results of Meeting
24/11/2016 Annual General Meeting Presentation
16/11/2016 Director Appointment
10/11/2016 Results Recommending Use of FerriScan in Sickle Cell Disease
09/11/2016 Change in substantial holding
28/10/2016 Appendix 4C - quarterly
24/10/2016 Notice of Annual General Meeting/Proxy Form
24/10/2016 Annual Report to shareholders
13/10/2016 Resonance Health commences involvement in diabetes study
30/09/2016 Customer Newsletter
29/09/2016 Appendix 4G
29/09/2016 Full Year Statutory Accounts
23/09/2016 Bone Marrow Iron - Regulatory Submission
13/09/2016 Becoming a substantial holder
07/09/2016 Expansion of Involvement in Pharmaceutical Clinical Trial
31/08/2016 Appendix 3B Issue of Employee Shares
30/08/2016 Preliminary Final Report
11/08/2016 Correction of Link - HepaFat-Scan International Publication
11/08/2016 HepaFat-Scan International Scientific Journal
26/07/2016 Appendix 4C - quarterly
29/06/2016 Customer News letter
29/06/2016 Appendix 3B
14/06/2016 Operational Update
30/05/2016 New UK Standards recommend FerriScan
29/04/2016 Appendix 4C Quarterly Cashflow Report
20/04/2016 Completion Minimum Holding Share Sale
05/04/2016 Second and Final Notice - Minimum Holding Share Sale
31/03/2016 Newsletter
25/02/2016 Half Year Accounts
23/02/2016 Minimum Holding Share Sale
01/02/2016 Appendix 4C - quarterly